Does inclusion of bioactive n-3 PUFAs in parenteral nutrition benefit postoperative patients undergoing liver surgery? A systematic review and meta-analysis of randomised control trials.
Zheng-Wei HeChao WangYong LiAwang DanzengFu-Bin LiuJia-Yu ShiPingcuo CirenXiao-Yin YuanCheng-Xian WuRun-Hu LanBin-Hao ZhangPublished in: BMJ open (2023)
We found that n-3 PUFAs can benefit patients undergoing liver surgery by improving liver function and certain clinical indexes and decreasing related inflammation factors. However, there are limited RCTs on the application of n-3 PUFAs for patients undergoing liver surgery. Further evidence of the benefit of n-3 PUFAs in these patients warrants further exploration.
Keyphrases
- patients undergoing
- minimally invasive
- coronary artery bypass
- end stage renal disease
- clinical trial
- newly diagnosed
- oxidative stress
- chronic kidney disease
- ejection fraction
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- study protocol
- percutaneous coronary intervention
- atrial fibrillation
- tissue engineering